Marcolino, Milena SorianoAnschau, FernandoKopittke, LucianePires, Magda CarvalhoBarbosa, Izabela GuimarãesPereira, Daniella NunesRamos, Lucas Emanuel FerreiraAssunção, Luís Fernando IsraelCosta, André Soares de MouraNogueira, Matheus Carvalho AlvesDuani, HelenaMartins, Karina Paula Medeiros PradoMoreira, Leila BeltramiSilva, Carla Thais Cândida Alves daOliveira, Neimy Ramos deZiegelmann, Patricia KlarmannGuimarães-Júnior, Milton HenriquesLima, Mauro Oscar Soares de SouzaAguiar, Rubia Laura OliveiraMenezes, Luanna Silva MonteiroOliveira, Talita FischerSouza, Maíra DiasFarace, Bárbara LopesCimini, Christiane Corrêa RodriguesMaurílio, Amanda de OliveiraGuimarães, Silvana Mangeon MereillesAraújo, Silvia FerreiraNascimento, Guilherme FagundesSilveira, Daniel VitórioRuschel, Karen BrasilOliveira, Thainara Conceição deSchwarzbold, Alexandre VargasNasi, Luiz AntônioFloriani, Maiara AnschauSantos, Veridiana Baldon dosRamos, Carolina MarquesAlvarenga, Joice Coutinho deScotton, Ana Luiza Bahia AlvesManenti, Euler Roberto FernandesCrestani, Gabriela PetryBatista, Joanna d'Arc LyraPonce, Daniela [UNESP]Machado-Rugolo, Juliana [UNESP]Bezerra, Adriana Falangola BenjaminMartelli, Petrônio José de LimaVianna, Heloisa ReniersCastro, Luís César deMedeiros, Cássia Regina GotlerVietta, Giovanna GrunewaldPereira, Elayne CrestaniChatkin, José MiguelGodoy, Mariana Frizzo deDelfino-Pereira, PoliannaTeixeira, Antonio Lucio2023-07-292023-07-292022-12-15Journal of the Neurological Sciences, v. 443.1878-58830022-510Xhttp://hdl.handle.net/11449/247863Background: Scientific data regarding the prevalence of COVID-19 neurological manifestations and prognosis in Latin America countries is still lacking. Therefore, the study aims to understand neurological manifestations of SARS-CoV 2 infection and outcomes in the Brazilian population. Methods: This study is part of the Brazilian COVID-19 Registry, a multicentric cohort, including data from 37 hospitals. For the present analysis, patients were grouped according to the presence of reported symptoms (i.e., headache; anosmia and ageusia; syncope and dizziness) vs. clinically-diagnosed neurological manifestations (clinically-defined neurological syndrome: neurological signs or diagnoses captured by clinical evaluation) and matched with patients without neurological manifestations by age, sex, number of comorbidities, hospital of admission, and whether or not patients had underlying neurological disease. Results: From 6,635 hospitalized patients with COVID-19, 30.8% presented reported neurological manifestations, 10.3% were diagnosed with a neurological syndrome and 60.1% did not show any neurological manifestations. In patients with reported symptoms, the most common ones were headache (20.7%), ageusia (11.1%) and anosmia (8.0%). In patients with neurological syndromes, acute encephalopathy was the most common diagnosis (9.7%). In the matched analysis, patients with neurological syndromes presented more cases of septic shock (17.0 vs. 13.0%, p = 0.045), intensive care unit admission (45.3 vs. 38.9%, p = 0.023), and mortality (38.7 vs. 32.6%, p = 0.026; and 39.2 vs. 30.3%, p < 0.001) when compared to controls. Conclusion: COVID-19 in-hospital patients with clinically defined neurological syndromes presented a higher incidence of septic shock, ICU admission and death when compared to controls.engCOVID-19DeliriumNeurologic manifestationsPrognosisArtigo10.1016/j.jns.2022.1204852-s2.0-85141757629